Centene Corporation (CNC) is a new-age multi-national healthcare solutions provider from the United States, specializing in the administration and implementation of healthcare programs and services. Founded in 1984 by Elizabeth ‘Betty’ Brinn, the company has its headquarters situated in the heart of St. Louis, Missouri. CNC's steady culmination to predominance boasts an annual revenue of over $100 billion, marking its territory as one of the largest players in the healthcare sector.
Centene's strategic service framework encompasses a broad spectrum of healthcare programs, including Medicaid and Medicare. This Fortune 100 company targets uninsured individuals and those who are under-insured, offering them a lifeboat of reasonable health coverage. CNC operates nationwide, providing coverage to over 23 million members across an impressive 50 states.
Centene follows a unique business model aimed at bridging the gap between the underprivileged and quality healthcare. The company operates with a mantra, "Better Health Outcomes at Lower Costs". True to its motto, they follow the local approach and work hand-in-hand with the community, creating jobs and promoting healthy lifestyle initiatives amongst locals. Their widespread portfolio of services makes them a one-stop shop for healthcare services, ranging from behavioral health, substance use disorders, specialty pharmacy services, to telehealth.
Centene Corporation’s successful business module has fortified its position in the healthcare industry. It continues to reinvent and adapt its offerings in line with the market’s evolving needs and the government's healthcare policies. Notable acquisitions, like WellCare Health Plans in 2020, have exponentially broadened CNC's market reach, thereby consolidating its leading position in the sector.
A company committed to ESG (environmental, social, governance) principles, Centene is dedicated to reducing its environmental impact and ensuring sustainable business practices. It has bagged numerous accolades favoring its relentless pursuit to make healthcare affordable and accessible for all, including a place in the Dow Jones Sustainability North America Index and its prestigious Gold level status in the American Health Association's Workplace Health Achievement Index.
Being a crucial player in the healthcare sector, Centene also diligently participates in various philanthropic initiatives. Through the Centene Charitable Foundation, the corporation provides grants to non-profit organizations that share its vision of providing community-based health outcomes.
In summary, Centene Corporation is not just a market leader in the American healthcare space, but it's a stalwart that believes in impactful social change through affordable and accessible quality healthcare. With its innovative approach, tenacity for growth, and its commitment to bettering lives, CNC is an indisputable heavyweight in its sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Cliff Donald Blessing, EVP and Chief Development Officer of Addus HomeCare Corp (NASDAQ:ADUS), sold 2,000 shares of the company's common stock on November 6, 2026, at a weighted average price of $124.18 per share. This transaction, revealed in a Form 4 filing, leaves Blessing with 10,183 shares of common stock directly owned. The sale involved multiple transactions ranging from $124.02 to $124.34.
Centene Corp. (CNC) shares dropped 5.97% on Friday, closing at $69.74, underperforming the broader market. The S&P 500 Index saw a slight rise, while the Dow Jones Industrial Average experienced a decline. This marks the second consecutive day of losses for Centene's stock.
This Zacks Analyst Blog highlights how the U.S. midterm election results are shaping the investment landscape, particularly for renewable energy, healthcare, and AI infrastructure stocks. It discusses how policy uncertainty creates opportunities across these sectors, with specific companies like Nextpower Inc., Centene, Microsoft, and Amazon seeing varied market reactions. The article emphasizes the importance of strong fundamentals amid evolving policy and regulatory conditions.
Shares of GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare surged following election results that confirmed Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty in the biopharmaceutical sector. Analysts project a strengthened recovery for the industry as drug pricing legislation is unlikely to dominate the new legislative agenda, fostering a predictable regulatory climate. UFP Technologies, in particular, saw a significant jump of 21.5%, contributing to its 51.1% year-to-date increase.
Centene Corp. (CNC) saw its stock surge by 12.64% to $76.01 on Wednesday, outperforming the broader market. The S&P 500 Index rose by 1.58%, and the Dow Jones Industrial Average increased by 3.03% on the same strong trading day. This marks the second consecutive day of gains for Centene's stock.
Shares of Medicaid-focused U.S. health insurers and hospital operators saw significant gains in early trading after Democrats secured a sweeping victory in the midterm elections, taking control of both the Senate and House of Representatives. Analysts believe this outcome could delay or avoid the implementation of certain policy changes from President Donald Trump's "One Big Beautiful Bill" that were expected to reduce Medicaid enrollment and constrain state healthcare payments. This political shift is seen as easing pressure on Affordable Care Act insurers and hospital operators, and potentially improving prospects for extending enhanced subsidies.
Cerenome, through its subsidiary CNSide Diagnostics, has secured a national in-network agreement with Aetna Health Plans for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration and Molecular Profile tests. This agreement, effective November 1, 2026, adds approximately 26 million Aetna members to CNSide’s contracted payer footprint, bringing their total covered lives to about 190 million (85% of private payers). This marks the first national CNSide payer agreement to cover both tumor cell enumeration and molecular profiling, enhancing patient access to critical diagnostic tests for CNS cancers.